Xcafal 100 Dry Syrup contains Cefpodoxime Proxetil 100 mg, a third-generation cephalosporin antibiotic effective against a broad spectrum of bacterial infections. It is indicated for the treatment of respiratory tract infections, including bronchitis and pneumonia, otitis media, pharyngitis, tonsillitis, and uncomplicated skin and soft tissue infections caused by susceptible organisms. Cefpodoxime Proxetil acts by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. The dry syrup formulation is designed for pediatric use, providing an easy-to-administer and palatable option for children who have difficulty swallowing tablets. After reconstitution, the syrup should be stored as per manufacturer guidelines and used within the recommended period to maintain efficacy. Dosage should be determined based on the severity of infection, patient age, and weight, following a healthcare professional’s prescription. Common side effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal pain. Hypersensitivity reactions, although rare, may occur in patients with a history of beta-lactam allergy. It is essential to complete the full course of therapy to prevent resistance development. Xcafal 100 Dry Syrup should be used with caution in patients with renal impairment and under medical supervision during pregnancy and lactation.